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Abstract: Atopic dermatitis (AD) is a common disease with worldwide prevalence, affecting 
up to 20% of children and 3% of adults. Recent evidence regarding pathogenesis has implicated 
epidermal barrier defects deriving from filagrin mutations with resulting secondary   inflammation. 
In this report, the authors comprehensively review the literature on atopic dermatitis therapy, 
including topical and systemic options. Most cases of AD will benefit from emollients to enhance 
the barrier function of skin. Topical corticosteroids are first-line therapy for most cases of AD. 
Topical calcineurin inhibitors (tacrolimus ointment, pimecrolimus cream) are considered second 
line therapy. Several novel barrier-enhancing prescription creams are also available. Moderate to 
severe cases inadequately controlled with topical therapy may require phototherapy or systemic 
therapy. The most commonly employed phototherapy modalites are narrow-band UVB, broadband 
UVB, and UVA1. Traditional systemic therapies include short-term corticosteroids, cyclosporine 
(considered to be the gold standard), methotrexate, azathioprine, mycophenolate mofetil, and 
most recently leflunamide. Biologic therapies include recombinant monoclonal antibodies acting 
on the immunoglobulin E / interleukin-5 pathway (omalizumab, mepolizumab), acting as tumor 
necrosis factor-α inhibitors (infliximab, etanercept, adalimumab), and acting as T-cell (alefacept) 
and B-cell (rituxumab) inhibitors, as well as interferon γ and intravenous immunoglobulin. Effi-
cacy, safety, and tolerability are reviewed for each medication.
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Introduction
Atopic dermatitis (AD; synonym: atopic eczema or eczema) is a common disease 
with worldwide prevalence. AD affects up to 20% of children and 3% of adults.1,2 
It is associated with the development of atopic respiratory disorders such as allergic 
rhinitis and asthma (40%–60% of cases) and persists beyond childhood in 40%–60% 
of cases.2 A preponderance of data indicates that AD is a genetic disease with variable 
expression that is highly influenced by immunologic and environmental factors.3 Origi-
nally, atopic dermatitis was thought to primarily be due to an abnormality in adaptive 
immunity due to dysregulation of Th1 and Th2 lymphocyte mediated immunity with 
inappropriate Th2-mediated inflammation leading to skin barrier dysfunction and 
pruritus. However, recent evidence points to atopic dermatitis being due to a primary 
barrier defect with resulting secondary inflammation. The barrier defect is due to null 
mutatons in the epidermal protein filagrin which is involved in normal   cornification 
of the epidermis as well as acting as a natural moisturizing factor in the stratum 
  corneum.4 On a population-based scale, 11%–15% of all cases of atopic dermatitis 
can be attributed to filaggrin null mutations.5Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Methods
The PubMed® database was comprehensively searched for 
English-language publications containing the keywords atopic 
dermatitis or atopic eczema. The database was last accessed   
on March 1, 2010. Articles discussing therapy of AD were 
selected for further review, with a focus upon recent articles 
(published within the last 5 years) and those   detailing novel 
therapies. Randomized, double-blind   placebo-controlled 
trials and meta-analyses of the literature were particularly 
sought, though other types of studies (including open-label 
trials and case series) were also reviewed.
Clinical presentation
AD is a chronic, relapsing dermatitis with pruritus as a major 
feature. Diagnostic features are reviewed in Table 1. Clini-
cally, eczematous patches and plaques are seen, which favor 
the face and extensor surfaces in young children (Figure 1) 
and flexor surfaces (including the antecubital and popliteal 
fossae, ankles, and neck) in older children (Figure 2) and 
adults. Lichenification from chronic scratching is   common 
(Figure 3). Nummular lesions commonly occur on the 
extremities (Figure 4).
The course and severity of AD varies widely. Patients may 
enjoy prolonged periods of remission, though periodic flares 
of disease activity are common. Cases may be graded as mild, 
moderate, or severe, depending the extent of skin   disease. 
The majority of cases develop before the age of 5 years.3 
  Resolution by adolescence occurs in many cases, though 
some patients will have persistence of disease into adulthood.2 
The signs and symptoms of AD are associated with a signifi-
cant detrimental impact on quality of life, with significant 
physical discomfort in addition to negative psychosocial 
consequences and impaired social development.2,3,6
Therapy of atopic dermatitis: 
overview
The most effective therapy of AD will involve a flexible plan 
that includes short-term treatment of flares and a long-term 
maintenance approach to skin care designed to prevent or 
minimize flares.7 Management of almost every case of AD 
will include topical therapy. For patients with mild to mod-
erate eczema, topical therapy may be entirely sufficient to 
control disease activity. Patients with more severe disease 
may require more advanced therapy including phototherapy 
or systemic therapy. An overview of treatment options is 
provided in Table 2.
Topical therapy
Topical therapy is integral to the management of chronic 
eczema. Patients with eczema have been objectively shown to 
have impaired skin barrier function compared to normal con-
trols using clinical measures such as skin hydration (reduced 
Table 1 Diagnostic features of atopic dermatitis3,7,13
Major features* • Pruritus
•   Eczematous eruption in a typical age-appropriate distribution (flexoral surfaces, ankles, neck age . 4 years, 
cheeks, forehead, outer limbs age , 4 years)
• Chronic and relapsing clinical course
• Tendency toward xerosis or “sensitive” skin
• Personal history of asthma or allergic rhinitis (or family history of atopy in patients , age 4 years)
• Age of onset under 2 years (if over 4 years of age)
Minor or associated features • Ichthyosis
• Palmar hyperlinearity
• Follicular findings (keratosis pilaris, perifollicular accentuation)
• Dennie-Morgan lines (infaorbital folds)
• Periorbital darkening
• Pityriasis alba
• Lichenification, prurigo lesions
• Environmental influence
• Intolerance to wool
• Tendency toward dermatitis at specific body locations (hands, feet, nipples, lips)
• elevated serum immunoglobulin e
• Tendency toward skin infections
• Abnormal vascular responses (facial pallor, delayed blanch response, white dermatographism)
• Ocular changes (keratoconus, anterior subcapsular cataract, recurrent conjunctivitis)
• Food intolerance
Notes: *Pruritus and at least three other features should be present for diagnosis.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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in eczema) and transepidermal water loss (increased in 
eczema).8 The majority of cases of eczema will be adequately 
managed with topical therapy. Flexible treatment strategies 
that include patient-centered plans for long-term maintenance 
as well as management of acute disease flares, result in the 
best chance for effective eczema control.
Daily interventions
Most patients with eczema have sensitive skin that is prone 
to xerosis and irritation. Using hypoallergenic skin care 
products is generally recommended. As seasonal flares 
are common, the use of a humidifier in the home, especially 
during low-humidity winter months, can have a positive 
impact in preventing eczema flares. Optimizing the bath-
ing method can be helpful in promoting the integrity of the 
skin’s barrier function. Limiting bathing to ten minutes per 
day, using warm (rather than hot) water, and using mild soap 
or body wash, will help to minimize irritancy. After gently 
toweling dry, emollients applied to slightly damp skin will 
help to minimize xerosis.
emollients
Emollients should be considered as first-line therapy for mild 
disease. Emollients may be applied multiple times daily, and 
especially after bathing. Continued use of emollients during 
periods of disease quiescence can reduce the tendency for 
eczema flares. In a recent study of 44 patients with eczema, half 
were randomized to emollient therapy and half were random-
ized to no treatment. The 22 patients not using emollient expe-
rienced a disease flare after a median 30 days; the 22 patients 
using emollient did not relapse during the 180 day follow-up 
period of the study.9 In a similar study of 52   children with 
eczema treated with mid potency topical steroid to lesional 
skin for two weeks, subsequent daily application of emollient 
Figure 4 Nummular eczema.
Figure 1 Atopic eczema affecting a young child’s face.
Figure 2 Flexoral eczema on the ankle of a child.
Figure 3 Lichenification from chronic eczema on the posterior neck.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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significantly improved xerosis and pruritus compared to no 
application of emollient.10 Proper emollient use also leads to 
a reduction in topical corticosteroid use as demonstrated in 
51 children with atopic dermatitis followed for one year.11
Patients are generally instructed to apply emollients 
“liberally,” though the clinical meaning of this term is sub-
jective. A recent of study of 67 pediatric patients (48 with 
eczema, 19 controls) found that 130 g/m2/week of emollient 
was adequate for 95.8% of patients.8 However, the study did 
not detect differences in clinical response.
Medical therapy
Topical corticosteroids (TCs) are the cornerstone of therapy 
for AD flares. During the past decade, topical calcineurin 
inhibitors (TCIs) have gained a prominent and often comple-
mentary role in AD management. Both TCs and TCIs may 
be regarded as immunomodulating medications. While TCs 
broadly inhibit the inflammatory pathway, TCIs inhibit the 
immune response in a more targeted fashion.12
Topical corticosteroids
TCs are considered first-line therapy for AD flares.13 These 
agents work by activation of nuclear glucocorticoid   receptors 
to alter expression of cytokines involved in the inflamma-
tory response. These medications are divided into seven 
classes based on potency as determined by vasoconstrictor 
assays, with I being the strongest, and VII the weakest. Com-
monly used options include low potency (class VII and VI; 
eg, hydrocortisone, desonide), mid-potency (class III–V; 
eg, triamcinolone, mometasone, fluticasone) to high-potency 
(class I–II; eg, fluocinonide, desoximetasone, betamethasone 
dipropionate, clobetasol, halobetasol)   corticosteroids.3 Avail-
able vehicles include ointments, creams, gels, lotions, liquids, 
and foams. These agents have a relatively low risk of cutane-
ous side effects when used twice daily in two-week cycles 
followed by at least a one week rest from use. Occlusion under 
plastic wrap can enhance the effectiveness. Ointments and 
creams will generally be the most effective in treating AD 
as these vehicles tend to be more moisturizing.
For managing flares, it is generally recommended to use 
mid-to-high potency TCs twice daily for up to two weeks 
on the trunk and extremities, and lower potency steroids on 
the face, intertriginous areas, and in young children. Once 
control is gained, topical steroids should be used intermit-
tently. While conventional wisdom dictates the use of the 
lowest-potency compound that brings relief, flares may 
be controlled more rapidly with shorter term use of higher 
potency preparations.
Topical corticostroids: efficacy
A multicenter study of 174 children with mild-moderate 
atopic eczema showed no significant difference in disease 
severity, symptom control, or quality of life between low 
potency (1% hydrocortisone) applied twice daily for 7 days, 
compared to higher potency (betamethasone valerate) TCs 
applied twice daily for 3 days followed by emollient alone 
for 4 days.14 In a study of 111 patients with chronic derma-
titis including AD, treatment with halobetasol propionate 
cream (superhigh potency) was associated with significant 
improvement in skin disease compared to vehicle, without 
reported systemic effects or skin atrophy.15 In a similar report 
detailing two vehicle-controlled trials of 124 and 100 adults 
with chronic dermatoses, halobetasol propionate cream was 
significantly more effective than vehicle (83% vs 28% of 
patients on active treatment and vehicle achieving “clear” to 
“markedly improved,” respectively.16
In another study of 55 children (aged 4 months to 
12 years) with AD, treatment with prednicarbate emollient 
cream 0.1% (mid-potency corticosteroid) daily for three 
Table 2 Treatment overview of AD
Lifestyle interventions emollients, bathing technique, 
humidification, 
avoidance of exacerbants
Topical therapy Topical corticosteroids (first line) 
Topical calcineurin inhibitors  
(second line) 
  tacrolimus, pimecrolimus 
Barrier enhancing creams
Phototherapy Narrowband UvB (311 nm) 
Broadband UvB (280–315 nm) 
UvA (315–400 nm) 
UvA I (340–400 nm) 
Psoralen UvA 
extracorporal photochemotherapy
Systemic therapies: Traditional Corticosteroids 
Cyclosporine 
Azathioprine 
Methotrexate 
Mycophenolate mofetil
Systemic therapies: Biologic Interferon-γ 
Immunoglobulin e/Interleukin-5 
Inhibitors 
  Omalizumab 
  Mepalizumab 
Intravenous immunoglobulin 
Tumor necrosis factor-alpha inhibitors 
  Infliximab 
  etanercept 
B- and T-cell Inhibitors 
  Alefacept 
  Rituximab
Ancillary therapies Antihistamines for control of pruritus 
Antibiotics (oral, topical) for control 
of secondary infectionClinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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weeks resulted in global evaluation improvement without 
evidence of hypothalamic–pituitary–adrenal (HPA) axis 
suppression.17 Multiple trials have established that there 
is no difference in efficacy of once daily application over 
twice daily application of TCS in the treatment of atopic 
dermatitis.18
Topical corticosteroids: safety
Adverse effects of TCs are generally reported only after 
long-term use and/or use of inappropriately potent prepara-
tions to given body sites. Cutaneous adverse effects can 
include formation of striae, telangiectasia, and atrophy. 
Systemic absorption of TCs is reported, potentially resulting 
in suppression of the HPA axis, but systemic adverse effects 
appear to be rare.
In a systemic review of the literature through 2005,   Callen 
et al concluded that the literature supports good overall 
safety of topical medications used to treat AD.19 Systemic 
exposure may occur with topical application of medications, 
but physiologic consequences are uncommon and systemic 
complications are rare and have only been reported for   topical 
corticosteroids.19
In a trial of children (aged 6 months–6 years) with mod-
erate to severe AD (mean body surface area involvement of 
51%), treated with desonide hydrogel 0.05% (a low potency, 
class VI corticosteroid) twice daily for four weeks, none 
of 34 patients who properly completed the study protocol 
showed evidence of adrenal suppression.20 However, a case of 
Cushing’s syndrome was reported in an 11-month-old infant 
associated with continuous use of moderate- to high-potency 
topical steroids for AD.21
In a multicenter, open-label trial in children aged 6 months 
to 18 years with moderate-severe AD (.20% body surface 
area involved), once daily treatment with fluocinonide 0.1% 
cream (class I/superhigh potency steroid) was not associ-
ated with HPA suppression (as determined by intravenous 
cosyntropin challenge) in any of 63 subjects. However, twice 
daily treatment was associated with HPA suppression in 
3/63 subjects.22 The risk of HPA suppression was no higher 
in infants and young children compared to older children 
and adolescents.22 In a study of 51 children (aged 3 months 
to 6 years) with extensive eczema ($35% BSA), fluticasone 
propionate (a mid potency steroid) applied twice daily for 3 
to 4 weeks was associated with no cutaneous adverse effects 
and only mild HPA suppression in 2/43 children.23 Similarly, 
no evidence of HPA suppression was seen in children with 
atopic dermatitis treated with either desonide 0.05% ointment 
or hydrocortisone 2.5% ointment for four weeks.24 In a study 
of 29 adults with chronic AD, lumbar bone mineral density 
scores were lower in a subset of patients with severe disease 
requiring long-term use of topical corticosteroids of potency 
higher than hydrocortisone.25 In a study of 125 patients with 
moderate to severe AD, over a third had osteoporosis or 
osteopenia, which was independent of oral or topical corticos-
teroid use within the prior five years. The authors speculated 
that the high rate of low bone mineral density may relate to 
the underlying inflammatory disease or long-term effects of 
remote exposure to corticosteroids.26
Topical corticosteroids: issues in patient education
In a questionnaire of 200 dermatology outpatients with 
atopic eczema (aged 4 months to 67 years), nearly three-
quarters were worried about side effects of topical corti-
costeroids, with a third expressing worry about skin atrophy 
and 10% expressing worry about systemic absorption. A 
quarter of patients had chosen not to use prescribed TCs 
due to their perception of risks, which the authors termed 
as “phobias,” out of proportion to any evidence of harm.27 
Recent evidence suggests that over 40% of caregivers of 
children with eczema have tried alternative or nontraditional 
therapies, with fear about TC side effects cited as the most 
common reason.28 This highlights the need for appropriate 
education of patients and caregivers to allay their concerns 
regarding the role of topical steroids in the ongoing therapy 
of chronic eczema.
Topical calcineurin inhibitors
TCIs, including tacrolimus and pimecolimus have been avail-
able for nearly 10 years and have been extensively studied 
in the management of AD. These agents work by inhibiting 
the phosphatase activity of calcineurin to block expression of 
cytokines.7 They thus act “downstream” in the glucocorticoid 
receptor pathway, and thus are thought to represent a more 
targeted way to limit inflammation and avoid many of the 
possible adverse effects of topical corticosteroids.
The labeled indication of TCIs is for application twice 
daily for up to 6 weeks as second line therapy for patients 
showing an inadequate response or adverse effects to 
topical corticosteroids. Pimecrolimus 1% cream and tac-
rolimus 0.03% ointment are approved for patients $ two 
years old, while tacrolimus 0.1% ointment is approved for 
patients $ 16 years old.7
TCIs may be used either as monotherapy or as combina-
tion or sequential therapy. A cost-utility comparison found 
that TCs are generally less expensive and more effective than 
TCIs, though individual clinical situations will arise in which 
TCIs are preferred (eg, topical corticosteroids ineffective or 
associated with actual or feared adverse effects).29Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Topical calcineurin inhibitors: efficacy
Multiple studies have confirmed the efficacy of TCIs, i  ncluding 
randomized, vehicle-controlled clinical trials, open-label   trials, 
and trials comparing TCIs to topical steroids (reviewed by 
Beck).30 In a recent meta-analysis of studies published from 
1997–2006, 19 reports including 7378 patients with AD treated 
with tacrolimus or pimecrolimus were reviewed. The authors 
concluded that both TCIs are more effective than placebo, that 
tacrolimus is more effective than low-potency topical steroids 
or pimecrolimus, and that tacrolimus is comparably effective 
as mid-potency topical steroids.31
In three 12-week, randomized vehicle-controlled trials, 
including nearly 1000 patients (children and adults) with 
moderate to severe AD, 28%–41% of patients achieved 
$90% improvement with tacrolimus ointment (0.03% or 
0.1%) compared to 7% with vehicle. In addition, 62%–78% 
achieved $50% improvement compared to 20%–27% treated 
with vehicle.32–34 In a study of 617 children and adults with 
mild to moderate AD, treatment with tacrolimus ointment 
(0.03%) for 6 weeks was associated with significant improve-
ment of skin disease (47.9% “clear” or “almost clear”) 
vs vehicle (29%; P , 0.001) by the end of the study, with a 
significant difference seen in degree of improvement by the 
fourth day of therapy.35
In a six-week study of 200 children with mild–moderate 
facial AD, pimecrolimus cream was significantly more effec-
tive than vehicle (clear/almost clear 74.5% vs 51%).36 In 
paired studies of children (aged 2–17 years), treatment with 
pimecrolimus 1% cream twice daily for 26 weeks resulted 
in significant improvement in global assessment compared 
to vehicle, with 34.8% of patients “clear” or “almost clear” 
compared to 18.4% of vehicle-treated patients (P , 0.001). 
Pimecrolimus showed significantly greater efficacy in treat-
ment of the face and neck compared to the rest of the body 
(P , 0.0001).37
Open-label 12 month studies in over 500 patients have 
confirmed these findings and shown ongoing efficacy.38,39 In 
a multicenter European study, 116 adults (aged $ 18 years) 
with moderate to severe AD were treated with tacrolimus 0.1% 
ointment for 12 months; 86% of patients showed “marked” to 
“excellent” improvement/clearance at the end of the study.39
Studies comparing TCIs with TCs have shown that similar 
improvement can be expected with both topical medications. In 
a trial of 570 adults with moderate to severe AD, 36% clinical 
improvement (as determined by the eczema area and severity 
index) was seen for both tacrolimus 0.1% ointment and hydro-
cortisone butyrate 0.1% ointment (mid potency   steroid), and 
both were superior to tacrolimus 0.03% ointment.40   Similar 
trials showed tacrolimus ointment (0.03% and 0.1%) to be 
clinically superior to a lower potency steroid (  hydrocortisone 
acetate 1%) in children and adults.41,42
In a randomized, double-blind study of patients with facial 
eczema, tacrolimus 0.1% ointment (n = 288) was superior to 
fluticasone 0.005% ointment (n = 280) when applied twice 
daily for three weeks, with more patients in the tacrolimus 
group showing $60% improvement compared to fluticasone 
(93% vs 88%; P = 0.026).43 In a similar trial of 73 patients 
(aged 2–49 years) with eczema unresponsive to topical ste-
roid, pimecrolimus 1% cream was associated with clinical 
improvement, especially in the head/neck areas.44
In a randomized, double-blind multicenter European study, 
658 adults with moderate to severe AD used either pimecroli-
mus or TCs (triamcinolone 0.1% and/or 1% hydrocortisone 
creams) twice daily to all affected areas until clear or for up 
to one year, with most patients using the medications con-
tinuously. Both therapies were effective, but pimecrolimus 
was associated with fewer adverse effects, including fewer 
skin infections and no striae formation (seen in three patients 
treated with TCs). 42% of patients were maintained on pime-
colimus as monotherapy.45 The study is particularly interesting 
in that use of the medications was unrestricted as to duration 
of application (eg, 2–3 weeks for TCs and six weeks for TCIs); 
the incidence of striae in steroid-treated patients is lower than 
might be expected under these circumstances.
In a two-phase study of 152 children (aged 2–15 years) 
with moderate to severe AD, twice-daily application of TCs 
(aclometasome ointment 0.05%) resulted in more rapid 
improvement of active eczema than tacrolimus 0.03% oint-
ment. However, once the dermatitis was stabilized, tacrolimus 
applied three-times weekly to previously affected skin for up 
to 40 weeks was significantly more effective than vehicle in 
maintaining disease stabilization.46 A similar study of 125 
children and adults with stabilized AD found that application 
of tacrolimus ointment (0.03% or 0.1%) three times weekly 
as maintenance therapy for 40 weeks, was associated with 
more flare-free days (177 vs 134; P = 0.003) and a longer 
time to first relapse (169 days vs 43 days, P = 0.037) com-
pared to vehicle.47
At least one large trial has compared the two TCIs to each 
other. In a study of adults with moderate AD (mean body 
surface area ∼16%), 98 were treated with tacrolimus 0.1% 
ointment and 90 were treated with pimecrolimus 1% cream. 
Tacrolimus ointment was associated with a significantly 
greater improvement in the eczema severity index (59%) com-
pared to pimecrolimus (43%; P = 0.01). Adverse effects were 
minor and did not differ between the treatment groups.48Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Topical calcineurin inhibitors: safety.  In clinical prac-
tice, the most common side effects of TCIs are application 
  site-irritation reactions, including pruritus and perceived 
burning sensation, particularly upon   initiation of treatment.39 
The burning sensation is thought to be due to transient local 
nerve fiber release of substance P and   calcitonin gene-related 
peptide.49
In a study of adolescents or adults with moderate to severe 
AD, treatment with pimecrolimus for three weeks applied 
either twice daily (n = 24) or four times daily (n = 25) resulted 
in clinical improvement in both groups. No significant dif-
ferences in adverse effects or serum levels of drug were seen 
between the groups, with 46/49 patients showing undetectable 
serum levels of the drug and three patients (one in the four 
times daily and two in the twice daily) showed detectable but 
low serum levels of the drug. Seven patients reported mild 
adverse effects (typically transient burning sensation at the 
application site).50
In an in vitro study, pimecrolimus was found to have 
significantly lower permeation through skin compared 
to tacrolimus and high-potency TCs, likely owing to the 
molecule’s higher lipophilicity.51 This may relate to studies 
suggesting lower relative efficacy and greater perceived safety 
of pimecrolimus.
In January 2006, the US Food and Drug Administration 
(FDA) changed the product label of both tacrolimus ointment 
and pimecrolimus cream to include a black-box warning 
regarding risk of cancer and lymphoproliferative disease, 
based largely on case reports of cancer in patients using 
TCIs, animal studies involving high-dose oral calcineurin 
inhibitors, and mechanism of action-based theoretical risks.7 
The blackbox warning based on inferred causality created 
controversy in the field of dermatology and increased the 
complexity of continuing to use these effective medications 
in clinical practice.
In a 2006 report by an American Academy of Dermatol-
ogy (AAD) Task Force, a review of available information 
led the authors to conclude that no causal proof existed that 
TCIs cause lymphoma or skin cancer.52 Since that time, 
a retrospective cohort observational study involving over 
950,000 patients with AD was performed.53 Sixteen cases 
of T-cell lymphoma were identified in patients treated with 
either topical tacrolimus or pimecrolimus between 2001 and 
2004. When charts were reviewed, at least four of these cases 
were suspected prior to exposure to TCIs and were excluded 
from further analysis. The odds ratio for T-cell lymphoma 
was determined to be 5.4 for tacrolimus (95% confidence 
interval: 2.5–11.8, P , 0.001) and was not significant for 
  pimecrolimus. No other subtypes of cancer were seen at 
increased incidence in the study population.53 Despite the 
small number of cases of lymphoma and the possibility that 
this was a pre-existing condition (as cutaneous lymphoma 
may clinically mimic dermatitis), this study represents the 
best evidence to date linking TCIs (tacrolimus at least) 
to cutaneous lymphoma. As suggested by the AAD Task 
Force, it is important for dermatologists and their patients 
to remain informed, to be aware of treatment indications and 
guidelines, and to be cognizant of the risks and benefits of 
any therapy.52
Prescription barrier creams. As discussed above, concerns 
about safety with ongoing use of both TCs and TCIs have 
spurred interest in the development of novel prescription 
emollients and barrier creams for use as ancillary or primary 
therapy of chronic eczema. At least four nonsteroid barrier 
creams have become available in recent years. These products 
may improve the signs and symptoms of AD by addressing 
the damaged skin barrier and providing anti-inflammatory 
action.7 Approved as “medical devices” rather than drugs by 
the FDA, these products are recognized to serve a structural 
role in cutaneous barrier function rather than exerting chemi-
cal or receptor-based effects.7 Moreover, clinical efficacy 
data for approval is less stringent for medical devices than 
for drugs.
Industry-sponsored studies have supported the efficacy 
of Tetrix®,54 Mimyx®,55 Atopiclair®,56–59 and Epiceram®.60 
All of these agents are marketed only under their registered 
  tradenames. Of these agents, Atopiclair is perhaps the 
most studied. The putative active ingredients of this com-
pound include hyaluronic acid, telmesteine, Vitis vinifera 
and   glycyrrhetinic acid, which have moisturizing, anti-
inflammatory, and antioxidant properties.56 Two studies in 
248 adults treated for 35–50 days showed found significant 
improvements in clinical parameters (surface area affected, 
severity index, and itch score) with Atopiclair compared 
to control.56,57 Similar results were seen in 202 pediatric 
patients (aged 6 months to 17 years) with AD treated for 
22 or 43 days, with Atopiclair showing clinical superiority 
to vehicle.58,59
Mimyx contains lipids as well as N-palmitoyletha-
nolamine which may negatively regulate the inflammatory 
response through agonist activity on mast cell cannabinoid 
receptors.7 A multicenter observational uncontrolled study of 
2456 patients (aged 2–70 years), reported that use of Mimyx 
was associated with clinical improvement (including pruri-
tus, erythema, excoriation, dryness, lichenification, scaling, Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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and sleep quality) and reduction of topical steroid usage.61 
EpiCeram is triple-lipid barrier repair cream containing cer-
amides, cholesterol, and free fatty acids. In a multicenter ran-
domized trial of 121 of patients (aged 6 months to 18 years) 
with moderate to severe AD, Epiceram was associated with 
similar clinical improvement (SCORAD severity index, pru-
ritus, and sleep score) at 28 days compared to mid-potency 
topical steroid (fluticasone), though the topical steroid was 
associated with more rapid improvement.60
Combination and sequential topical therapy. The most 
effective therapeutic approach is to combine   therapies in a 
fashion that is tailored to the individual patient. Combin-
ing treatments offers the advantage of gaining benefit from 
medications with different and complimentary   mechanisms 
of action while limiting concerns regarding overuse of a 
single agent.62,63
In a 16 week study of 221 patients with chronic eczema, 
use of TCs twice weekly in addition to emollient resulted 
in a 3.5-fold reduction in disease relapse compared to use 
of emollient alone.64 In a three-week study of 57 patients 
with AD, patients treated for 3 weeks concomitantly with a 
mid-potency steroid (clocortolone pivalate) and tacrolimus 
0.1% ointment showed significant improvements in a variety 
of clinical parameters (including excoriation, induration, 
erythema, crusting, and lichenification) compared to mono-
therapy with either medication.65
A recent study in 31 pediatric patients showed clini-
cal improvement in eczema severity with a combination 
approach, using TCIs, TCs, and emollients. During the 
induction phase, children with active eczema (2, 25, and 4 
with mild, moderate, or severe disease, respectively) were 
treated for two weeks with tacrolimus ointment (0.03%) in 
the morning and a topical steroid (variable potency) in the 
evening, followed by a two-week period of tacrolimus twice 
daily on weekdays and on weekend mornings with TCs on 
weekend evenings. This was followed by a two-week period 
without TCs in which tacrolimus was applied twice daily, then 
a six week period with application of emollient alone with 
tacrolimus used when necessary. Improvements in disease 
severity indices, pruritus, and sleep disturbance were seen.66 
This study illustrates that combined treatment is beneficial at 
improving outcomes while limiting potential adverse effects 
that may result from overuse of an individual medication. It 
also illustrates that combined therapy regimens are poten-
tially complex and highlights that the treatment plan should 
be tailored to the individual situation to avoid confusion and 
maximize adherence.
Use of wet-wrap therapy (WWT) may enhance the 
efficacy of topical treatments. This involves applying topi-
cal medication then occluding the body area with a damp 
dressing. Advantages include rapid response and effective 
relief of symptoms. Disadvantages include higher cost, incon-
venience, a need for specialized training, and an increased 
potential for adverse effects from occluded corticosteroids 
(including systemic absorption, atrophy, and striae), and 
increased incidence of skin infection requiring antibiotics.67–69 
Short-term WWT with diluted TCs was found, in a study 
of 8 prepubertal children, not to influence bone turnover or 
short-term growth.70
Adherence to topical therapy.  Lack of adherence to therapy 
is a barrier to effective treatment, and this may be particularly 
true as relates to topical therapy. In a study of 37 children 
with AD prescribed triamcinolone 0.1% cream, usage of 
medication was monitored using electronic devices in the 
tubes and by measuring the weight of the tube after 4 weeks. 
Mean adherence to therapy throughout the study was only 
32%, with higher adherence on the days surrounding the 
office visits.71 The authors concluded that better adherence, 
which might be achieved by more frequent follow-up visits, 
might be associated with better clinical outcomes and less 
need for systemic therapy.
Phototherapy
Phototherapy exerts beneficial effects on chronic skin   diseases 
such as AD through several mechanisms, including reduction of 
Langerhans cells, induction of immunomodulatory   cytokines, 
and promoting apoptosis of infiltrating T   lymphocytes.72 When 
chronic AD is not controlled adequately with topical therapy, 
phototherapy should be considered as a second-line treat-
ment due to its efficacy and and favorable risk–benefit profile 
compared to most systemic agents. Phototherapy will often 
be a part of a multitherapeutic approach involving topical 
treatments and perhaps systemic treatments.
Ultraviolet A and ultraviolet B
Early phototherapy trials for patients with AD compared 
  combined UVA and UVB treatment against either modality 
alone, with variable results. In two half-sided studies   involving 
43 patients with AD, combined UVA and UVB was signifi-
cantly more effective than either UVA or UVB alone.73
Advancement of phototherapy technology brought clini-
cal studies of narrow-band UVA and medium dose UVA1 (50 
J/cm2). In a trial of ten patients with severe generalized AD, 
exposure of one side of the body to high-dose UVA1 and Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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exposure of the contralateral side to half that dose (medium 
dose UVA1) five times weekly for three weeks, resulted in 
significant improvement over baseline (29%–38%) which 
was comparable for both sides.74 In a study of 32 patients 
with severe eczema, treatment with medium-dose UVA1 
therapy (50 J/cm2 5 times per week for 3 weeks), resulted 
in significant improvement which persisted one month after 
completion of therapy. However, disease severity returned to 
baseline by the third month post-treatment.75
In a pilot study, all five patients with severe atopic eczema 
treated with narrow-band UVB showed improvement of the 
disease after three weeks of therapy.76 In a study of 73 adults 
with moderate to severe atopic eczema treated with photother-
apy twice weekly for 12 weeks, NB-UVB was more effective 
than UVA in reducing disease severity.77A half-sided study of 
12 patients with severe chronic AD showed equivalent disease 
improvement (64%–65%) after phototherapy with PUVA or 
NB-UVB administered three times weekly for 6 weeks.78 
Recent informative studies have compared medium-dose 
UVA1 to NB-UVB. In a study in which 13 adults (aged 20–56 
years) with chronic AD received half-sided phototherapy three 
times weekly for 8 weeks, NB UVA and medium dose UVA1 
were both equally effective in reducing disease severity.72 In 
a comparative crossover study of phototherapy modalities, 
28 patients completed separate 6 week courses of both UVA1 and 
NB-UVB phototherapy. Both therapies were equally effective 
in significantly decreasing scores for pruritus and clinical 
severity.79 A few studies have directly compared phototherapy 
to TC treatment. In a multicenter study of 53 patients with 
AD, high-dose UVA1 was significantly more effective than 
treatment with either fluocortolone or combined UVA-UVB 
therapy.80 In a study of 21 adults with severe AD, UVB photo-
therapy three times weekly for 12 weeks was associated with 
a 68% reduction in disease severity and an 88% reduction 
in TC use. 15/24 continued to show benefit 24 weeks after 
discontinuing UVB.81
extracorporeal photopheresis
Extracorporeal photopheresis (ECP) involves the irradiation 
of blood fractions in the presence of psoralen and is thought 
to suppress pathogenic clones of T lymphocytes. In a study 
of seven patients (median age 47 years) with severe refrac-
tory atopic eczema, extracorporeal photopheresis (consisting 
of two treatments on successive days every two weeks for 
12–20 weeks) was associated with a mean 28% decrease in 
disease severity score.82 Although associated with low toxic-
ity, a primary drawback to ECP is that it is generally only 
available at tertiary care centers.
Phototherapy: summary
In a systematic review of the literature regarding photo-
therapy and AD, nine studies meeting inclusion criteria were 
analyzed. The authors concluded that UVA1 may be most 
effective at controlling acute flares of AD, while NB-UVB 
may be most effective in managing chronic AD.83 In another 
literature survey of phototherapy for a variety of nonpsoriatic 
skin conditions including AD, vitiligo, cutaneous lymphoma, 
and chronic urticaria, 28 articles were reviewed. Most 
patients in these studies had a primary diagnosis of either AD 
(n = 719) or generalized vitiligo (n = 305).84 Other common 
diagnoses included cutaneous lymphoma, chronic urticaria, 
and polymorphic light eruption. The authors concluded that 
based on its excellent safety profile and equivalent to supe-
rior efficacy, NB-UVB should be considered as the first-line 
phototherapy modality for these conditions.84
Phototherapy will not be beneficial for all patients with 
AD. Some will not tolerate the associated heat and sweating, 
though many phototherapy units are now equipped with fil-
tering and cooling systems. A small number of patients with 
AD will have photosensitivity or co-existing polymorphous 
light eruption.85 While an increased risk of skin cancer is 
seen with prolonged PUVA therapy, a ten-year study found 
no evidence of an increased skin cancer risk in 195 psoriasis 
patients receiving broadband or NB-UVB.86
Systemic therapies: overview
For particularly severe cases of eczema, systemic therapy 
may be required for management of acute flares or to 
suppress the activity of chronic disease. These therapies 
may be broadly grouped into traditional medications and 
biologic agents (targeted monoclonal antibodies). A sys-
tematic review of the literature found 37 studies totalling 
979 patients with severe atopic eczema treated with systemic 
therapy. Eleven studies showed cyclosporine to be effective. 
IFN and azathioprine were shown effective in randomized, 
controlled trials, mycophenylate mofetil was effective in 
two small studies. Systemic steroids were not adequately 
studied to recommend; IVIG and infliximab were not sup-
ported.87 Since this review was published, several trials of 
both traditional agents and newer biologic options have 
become available to guide clinical decisions.
Systemic therapies: traditional
Corticosteroids.  Corticosteroids act through binding cyto-
plasmic receptors which are then translocated to the nucleus 
to regulate the transcription of multiple genes involved in 
the inflammatory cascade. Though often highly effective in Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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eliminating the skin inflammation underlying the dermati-
tis of AD, systemic corticosteroids are not recommended 
for chronic therapy for AD owing to a high likelihood of 
significant adverse effects.88 Well-known complications of 
systemic corticosteroids include suppression of the HPA 
axis, hyperglycemia, osteoporosis, avascular necrosis of the 
hip, hypertension, ocular changes (posterior subcapsular 
cataracts, glaucoma), altered immune function, and altered 
body habitus. These risks may be both dose-dependent 
and dose-independent and are generally more likely with 
prolonged treatment. Children on prolonged corticosteroid 
therapy are particularly at risk for growth suppression and 
posterior subcapsular cataracts.88
In clinical practice however, systemic corticosteroids are 
not uncommonly used as short-term “rescue-therapy” for 
severe flares of disease.89 Often, oral prednisone (1 mg/kg/day, 
or equivalent) tapered over a 2-week period will quell a flare 
and allow ongoing topical maintenance therapy. Somewhat 
surprisingly, there have been few clinical studies to formally 
evaluate this therapy method.
In an Italian study of seven children with severe AD 
unresponsive to standard therapy, an intravenous bolus of 
methylprednisolone (20 mg/kg/day) for three days resulted in 
clinical improvement for several months in 5/7 patients, with 
transient lymphopenia being the only reported side-effect.90 
Cases of rebound flaring of AD after oral corticosteroids 
have been reported,91 and this highlights the importance 
using topical therapy both as a mainstay of therapy and 
particularly during severe flares which may require more 
intensive systemic therapy.
Cyclosporine.  Cyclosporine is the best-studied treatment 
for severe chronic eczema and is considered by many authors 
to represent the “gold standard” for systemic treatment of 
the severe manifestations of this disease. Cyclosporine’s 
cellular mechanism of action involves binding cyclophilin; 
this complex then inhibits the phosphatase activity of cal-
cineurin, thereby blocking the activation of transcription 
factor NF-AT (nuclear factor of activated T cells).88 In a 
multicenter, double-blind, placebo-controlled crossover study 
involving 33 patients with severe chronic atopic dermatitis, 
therapy with cyclosporine for 8 weeks was associated with 
highly significant improvement of quality of life parameters 
by multiple clinical indices.92
In a randomized double-blind trial of 38 adults with 
severe eczema, cyclosporine (2.7–4 mg/kg/day for 
6 weeks) was significantly more effective than   prednisolone 
(0.5–0.8 mg/kg/day for 2 weeks) in achieving a stable remis-
sion, with 6/17 patients on cyclosporine remaining clear 
12 weeks after active treatment compared to 1/21 patients 
on prednisolone.93 Cyclosporine therapy is generally associ-
ated with a rapid response. In a meta-analysis of 15 studies 
including 602 patients with severe eczema, treatment with 
cyclosporine was associated with a pooled mean decrease in 
disease severity of 22% (3 mg/kg/day) to 40% ($4 mg/kg/day) 
after 2 weeks of therapy. The relative effectiveness was 55% 
after 6–8 weeks of therapy.94 Cyclosporine can be used in 
both adults and children. The authors of a meta-analysis 
suggest that cyclosporine may be better tolerated in children 
compared to adults.94 However; cyclosporine use in children 
has been linked to lower bone mineral density.95
Cyclosporine is reported to have efficacy lasting long 
beyond the active therapy interval. In a follow-up study 
of patients with severe eczema treated with cyclosporine 
(5 mg/kg/day for 1–2 treatment periods of 6 weeks), 35 of 
37 remained in remission two years after their last dose.96 
Due to predictable dose related adverse effects (primar-
ily renal impairment and hypertension, but also gingi-
val hyperplasia, hypercholesterolemia, hypertrichosis, 
tremor, and fatigue), treatment of atopic dermatitis with 
cyclosporine is generally short-term (under 6 months). In 
a study of 73 patients (mean age 33.8 years) with severe 
atopic dermatitis treated with cyclosporine for at least 
6 months (mean duration of therapy 1.3 years), 56 (77%) 
responded to therapy. 10%–15% of patients experienced 
renal impairment (serum creatinine .30% baseline) 
or hypertension. 33/73 (45%) of patients experienced 
remained in remission for at least three months. 8% of 
these patients experienced a rebound of disease shortly 
after discontinuation of cyclosporine.97
Methotrexate.  Methotrexate (MTX) inhibits DNA synthe-
sis by substrate competition with dihydrofolate reductase. 
It is generally dosed weekly with oral delivery more com-
mon than intramuscular or intravenous. MTX (mean dose 
15 mg/week) was shown to be effective in controlling 
chronic eczema symptoms; 11/12 patients completed a 
24-week trial (one discontinued due to adverse effects) mean 
disease activity (measured by the six area six sign atopic 
dermatitis score) improved by 52% in subjects completing 
the trial, with 8/9 patients showing continued improvement 
12 weeks after stopping methotrexate.98 In a retrospective 
study of 20 patients with chronic – eczema on weekly MTX 
(7.5–25 mg/week), 75% of patients showed improvement at 
three months, with 65% of patients showing an improvement 
in global assessment score .70%. Ten percent of patients 
discontinued the medication due to nausea and increased 
liver enzymes.99Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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MTX therapy (dosed 7.5–25 mg administered orally or 
intramuscularly) was associated with a ∼45% improvement in 
quality of life measures in a study of 20 adults with chronic 
moderate-to-severe atopic dermatitis. A quarter of patients 
in this study had nausea and increased liver enzymes, lead-
ing to discontinuation in therapy for three. An additional 
patient developed peripheral neuropathy which resolved 
when the medication was discontinued.100 In another study, 
MTX (10–20 mg weekly) was effective in 9/9 adult patients 
with chronic eczema, with 6/9 patients achieving complete 
remission after 3 months.101
In a case series, 3 of 4 elderly patients with chronic atopic 
eczema (aged 71–83 years), treatment with low-dose MTX, 
dosed initially up to 7.5 mg, was effective in controlling 
the skin disease. After several months of therapy, doses for 
the three responders were decreased to 2.5 mg weekly for 
2 patients and discontinued entirely for one patient, with 
ongoing remission.102
The onset of improvement with MTX is generally slower 
than with cyclosporine, with onset 4–8 weeks for methotrex-
ate compared to 2 weeks for cyclosporine.99 MTX requires 
careful clinical and laboratory monitoring. Gastrointestinal 
disturbance, anorexia, fatigue, stomatitis, and alopecia are the 
most common adverse effects.88 Hepatotoxicity (including 
cirrhosis) and bone marrow suppression (including pancy-
topenia) are the most serious potential adverse effects. Renal 
impairment and pulmonary toxicity (interstitial pneumonitis) 
are also reported. Patients with liver disease or significant 
ethanol intake, as well as patients with renal dysfunction, 
should not be treated with MTX.
Azathioprine. Azathioprine is a thiopurine prodrug which 
is activated to 6-thioguanine, which is further activated to 
several effectors which block purine synthesis. With proper 
laboratory monitoring, azathioprine is a relatively safe medi-
cation. Adverse effects include myelosuppression, gastroin-
testinal disturbance (nausea, vomiting, diarrhea, hepatitis, 
pancreatitis), and risk of infection and malignancy (particu-
larly hematologic). Selecting the dose of azathioprine based 
on the activity of thiopurine methyltransferase (TPMT), 
which is a key factor in azathioprine-induced myelotoxicity, 
may limit adverse effects.103
In a 12 week, placebo controlled trial of 63 patients 
with chronic eczema, azathioprine was associated with a 
significant improvement in disease activity compared to 
placebo (37% vs 20%). Nine patients (7 on azathioprine, 2 
on placebo) withdrew from the study.103 In a retrospective 
review of 37 patients with chronic atopic eczema treated with 
azathioprine over an 18 year period, 15/37 (40.5%) achieved 
remission in a median period of 5 months; ten patients did 
not respond adequately, and five had adverse reactions 
requiring discontinuation of the drug.104   Azathioprine has 
also been studied in children with severe eczema. In a ret-
rospective study, 28/48 children had an excellent response 
to azathioprine; 13/48 had a good response, and 7/48 had 
a poor response.105 The authors recommended dosing the 
medication at 2.5–3.5 mg/kg in patients with a normal 
TPMT level.105
Mycophenolate mofetil.  Mycophenolate mofetil (MMF) 
is derived from mycophenolic acid, which acts as an 
inhibitor of de novo purine   biosynthesis, by inhibition 
of inosine monophosphate dehydrogenase, the enzyme 
which produces guanosine-5-phosphate from   inosine- 
and xanthine-5-phosphate. Lymphocytes are   particularly 
  targeted by this cytotoxic effect as these cells lack a 
highly active purine salvage pathway. MMF is generally 
well-tolerated. Adverse effects include gastrointestinal 
disturbance and rare bone marrow suppression.88 In a study 
of ten patients with severe AD, treatment with oral MMF 
(1 g twice daily for the first week then 2 g twice daily for 
11 weeks) was associated with a 68% improvement in 
disease severity (SCORAD index), without any reported 
adverse effects.106 In an   open-label pilot study, 10 patients 
were treated with MMF 1 g twice daily for 4 weeks, with 
a 55% reduction in disease severity (SCORAD index) 
by week 4. Of the 7 patients completing the 20 week 
follow-up period, reduction of disease severity was 74%; 
6/7 had no relapse of disease. One patient dropped out 
during therapy due to herpes keratitis.107
In a retrospective review of 20 patients with severe 
AD treated with MMF, 17/20 patients responded, within 
4 weeks of beginning therapy. 10 patients experienced 
remission and discontinued MMF; 7 continued MMF as 
maintenance therapy.108 Infectious complications were 
relatively high in this study, with 5/20 developing viral 
infections (zoster in 4, herpes simplex in one) and 2/20 
developing   Staphylococcus aureus skin infections. As the 
study was uncontrolled, attributing the infections to MMF 
is conjecture.
A retrospective review of 14 patients with severe 
childhood atopic dermatitis treated with MMF (dosed at 
30–40 mg/kg daily in adolescents and 40–50 mg/kg daily 
in younger children), 8/14 patients obtained 90%–100% 
improvement and an additional 5/14 experienced 60%–90% 
improvement, with one nonresponder. Initial responses were 
seen at a mean of 4 weeks and peaked at a mean of 9 weeks. 
No adverse effects were reported.109Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Other nonbiologic systemic agents.  Leflunamide is an 
i  mmunosuppressant which blocks de novo pyrimidine synthe-
sis and is approved for treatment of rheumatoid arthritis and 
psoriatic arthritis.110 In published case reports, two patients 
with severe, near-erythrodermic atopic dermatitis achieved 
long-term (20 months) improvement with leflunamide (20 mg 
daily after three days of 100 mg as loading dose) as mono-
therapy.111 A third with chronic eczema showed only partial 
response on leflunamide and continued to require systemic 
corticosteroid.110 Significant adverse effects were not reported 
in these three patients.
In a recent case report, everolimus (a rapamycin-derived 
immunosuppressive used in organ transplant patients) was not 
found to be effective in two patients with severe AD concur-
rently on either prednisone or cyclosporine.112
Systemic therapy: biologic agents
Biologic agents are produced by living systems and are 
  protein-based therapies including soluble receptors, mono-
clonal antibodies, or cytokines designed to modulate the 
immune response.113 Generally indicated for treatment of 
autoimmune inflammatory diseases such as rheumatoid 
arthritis, Crohn disease, psoriatic arthritis and moderate-
to-severe plaque psoriasis, injected “biologic” agents have 
been tested off-label as a potential therapy for severe AD. 
These agents may represent a more targeted and less toxic 
option. Of the agents discussed here, interferon has been 
available for the longest time and has the most clinical data 
supporting its use.
Recombinant interferon.  As AD has been shown to be 
associated with low interferon (IFN)-γ levels leading to 
elevated interleukin-4   levels and upregulation in immuno-
globulin E levels, IFN was identified as a potential immu-
nologic therapy for severe AD. In an early trial of IFN-α 
administered 3 times weekly, an adequate response was seen 
in 5/13 subjects.114 In a   subsequent randomized trial of 83 
patients with moderate to severe AD, treatment with recom-
binant IFN-γ (as 50 mg/m2 daily subcutaneous injection for 
12 weeks) was superior to placebo in both patient-assessed 
and   physician-assessed response, with 45% of the IFN-group 
achieving .50% improvement compared to 21% of the 
placebo group (P = 0.016). Headache, myalgia, and chills 
occurred in 30%–60% of IFN-γ treated patients.115 A similar 
study found recombinant IFN-γ to induce significant improve-
ment in 8 of 14 (57%) of patients treated for 6 weeks, with 
half of responders showing ongoing improvement three 
months after therapy was discontinued.116
Treatment with IFN-γ (50 micrograms/m2 daily or every 
other day) in 15 patients for at least 22 months was associ-
ated with significant reduction in body surface area (61.6% 
baseline involvement vs 18.5% involvement at 24 months) 
and overall clinical improvement, with no significant adverse 
effects reported.117 In a randomized, placebo-controlled study 
of 51 patients with severe AD treated with IFN-γ adminis-
tered subcutaneously three times weekly for 12 weeks, both 
low dose (500,000 U/m2) and high dose (1.5 million U/m2) 
were associated with reduced disease severity compared to 
placebo, with the high-dose group showing a faster initial 
response.118
In contrast, IFN-α 2b (9–15 million U/week for 4–6 weeks) 
was judged ineffective in treating AD in 8 subjects, with 4/8 
patients showing exacerbation of their disease.119 IFN-α 2a 
administered daily for 3 weeks was associated with only 
short-lived (,3 weeks) improvement in severe AD in 8/9 
treated patients.120
While IFN-γ has been shown to be highly effective in 
a subset of patients, its use is limited by tolerability (high 
incidence of flu-like syndrome), a relatively low response 
rate, and high cost. Baseline serum IgE , 1500 IU/ml and 
serum eosinophils ,9% may be predictive of a favorable 
clinical outcome.121
Intravenous immunoglobulin.  Intravenous immunoglobu-
lin (IVIG) is pooled purified immunoglobulin obtained from 
the serum of multiple donors. It is used as therapy for primary 
immunodeficiency, Kawasaki disease, idiopathic thrombo-
cytopenic purpura, and has been tried in other inflammatory 
diseases including AD. IVIG is relatively safe but remains 
expensive. Infusion reactions, including headache, fever, 
chills, mylagia, and fatigue, occur in up to 6% of patients. 
Other adverse events including hemolysis, acute renal failure, 
and transmission of viruses, are rare.88
In a study of nine patients with severe AD (and one with 
hypereosinophilic syndrome) administered IVIG (2 mg/kg 
monthly × 6 months), six showed slight clinical improve-
ment. No significant change was seen in serum IgE levels. 
The authors concluded that IVIG was associated with no 
benefit.122 In a case series, three patients with severe AD 
requiring systemic corticosteroid were treated with monthly 
IVIG (2 mg/kg). Each showed clinical improvement and were 
able to decrease their steroid dose.123
In a comparative trial of 12 infants with severe AD, 
five infants (aged 7–12 months) received IVIG 2 mg/kg 
monthly for three months. An age-matched control group of 
seven infants received topical steroid therapy only. After three Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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months, the SCORAD index was significantly (P = 0.01) 
improved in the group treated with IVIG.124
When these and other initial studies and other case reports 
in the English literature (up to the year 2001) were reviewed, 
Jolles identified 32 patients with severe AD treated with IVIG 
and determined that improvement was seen in 61%, with 
children showing a better response rate (90%) compared to 
adults (48%), with a longer duration of response.125 Children 
generally improved with IVIG as monotherapy, while adults 
were generally administered IVIG concurrently with other 
systemic agents.125
In a small trial, ten adults with recalcitrant AD were 
treated with IVIG given as 1 mg/kg daily for two days. 
When assessed at day 30, no significant improvement was 
observed by either SCORAD index or global severity mea-
sures.126 In an open-label study, six adults with severe AD 
were treated with six monthly cycles of IVIG (2 mg/kg) then 
followed for three additional months. Four of the six patients 
showed significant clinical improvement and demonstrated 
reduction in pathogenic T cell levels.127 In a comparative 
study of 14 patients with severe atopic dermatitis, treat-
ment with intravenous immunoglobulin (2 g/kg as a single 
infusion) was associated with significantly lower efficacy 
compared to treatment with cyclosporine (4 mg/kg/day for 
three months).128
TNF-inhibitors. As TNF-α and TNF-dependent cytokines 
are involved in the immune-based inflammatory etiology 
of AD, blockade of this effector molecule is a plausible 
therapy target for chronic eczema. Currently available TNF-
inhibitors include infliximab, etanercept, and adalimumab. 
To date, published reports have detailed experience with 
infliximab and etanercept, but not adalimumab, for chronic 
eczema.
In a prospective trial of 9 patients with AD, infliximab 
(5 mg/kg administered by intravenous infusion at week 0, 2, 
6, then every 8 weeks for 4 additional doses) was associated 
with clinical improvement during induction (53% improve-
ment at week 2) but not maintenance, with only 2/9 patients 
showing sustained improvement by the end of the study.129 
In a case report, two adults with chronic AD experienced 
complete resolution on etanercept (50 mg injected subcutane-
ously twice a week) for 8–11 months of therapy and remained 
in remission for 26–31 months after discontinuation.130 In 
contrast, etanercept was associated with no improvement in 
two pediatric patients with AD.131
Adverse effects of TNF therapy. As a class, TNF therapy is 
associated with increased risks of infection and malignancy 
(particularly hematologic). Of 12 patients with AD treated 
with TNF inhibitors, one developed an infliximab-infusion 
reaction, one developed an urticarial   reaction to etanercept, 
and one developed a methicillin-  resistant Staphylococcus 
aureus infection while on etanercept.113
TNF-inhibitors are also associated with triggering 
an eczema-like drug eruption. In a prospective study of 
92 patients treated for indications other than skin disease/ 
psoriasis, 15 (16%) developed eczema during treatment with 
infliximab.132 A personal history of atopy was predictive of 
this medication-response.132
Alefacept.  Alefacept is a fully human fusion protein 
derived from immunoglobulin G1 and lymphocyte function-
  associated (LFA)-3 that selectively inhibits T-cell activation 
and reduces memory T cells. In a 16 week study, nine adults 
with severe AD were administered alefacept as a weekly 
intramuscular injection. Two of nine subjects achieved an 
Eczema Area Severity Index score of 50%; three of nine sub-
jects achieved a Physician Global assessment score of mild to 
almost clear. Importantly, an equal number of patients (3/9) 
showed a worsening of their disease as showed a significant 
improvement.133
IgE/IL-5 pathway inhibition: omalizumab.  Omalizumab 
is a recombinant humanized monoclonal antibody to immu-
noglobulin E, with specificity to selectively bind to free IgE 
and membrane-bound IgE on B cells. The role played by IgE 
in AD is unclear, with limited data to support this molecule 
as a major pathogenic effector.113 In a literature review, Flohr 
et al estimated that only a third of patients with AD show 
true IgE sensitization.134 However, given the central role of 
IgE in atopy and the efficacy of anti-IgE therapy in aller-
gic asthma and allergic rhinitis, a small number of studies 
have been conducted to study the effect of omalizumab on 
chronic severe AD. In four case series and one case report, 
30/35 patients (86%) with AD have shown improvement with 
omalizumab therapy.
In a prospective study of 21 patients (aged 14–64 years) 
with both AD and moderate-to-severe persistent allergic 
asthma, all showed statistically significant improvement 
of their skin disease, regardless of baseline serum IgE 
levels.135 In a retrospective study, 5 of 7 patients treated 
with omalizumab for their asthma, had improvement in 
their concurrent AD by the third month of therapy.136 In 
another retrospective report, 3/3 patients (aged 10–13 
years) treated with omalizumab (every two weeks, doses 
up to 400 mg) for their severe eczema, showed improve-
ment after 2–12 weeks.137Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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A case report detailed improvement in the pruritus 
  associated with chronic eczema in a 41 year old man treated 
with omalizumab 375 mg every 2 weeks for three months.138 
In contrast, none of three patients with severe AD (aged 
34–48 years) treated with omalizumab (450 mg administered 
subcutaneously every other week) showed any improve-
ment after 4 months of therapy, though concurrent asthma 
improved in one patient.139
No significant adverse effects have been reported in 
the above studies. Surveillance of 39,510 patients taking 
omalizumab for all indications revealed a 0.09% rate of 
anaphylaxis, triggering a black-box warning on the label of 
this medication.113
IgE/IL-5 pathway inhibition: mepolizumab.  Mepoli-
zumab is a humanized monoclonal anti-IL-5 antibody that 
has been studied for treatment of eosinophil-mediated disease 
such as asthma, AD, eosinophilic gastrointestinal disease, 
and hypereosinophilic syndrome. IL-5 enhances production 
and maturation of eosinophils, and blockade of IL-5 with 
mepolizumab inhibited infiltration of eosinophils into aller-
gen-injected skin in 24 subjects with AD.140 In a prospective 
trial, patients with severe AD were administered two doses 
of mepolizumab (750 mg intravenous, one week between 
doses, 18 subjects) or placebo (22 subjects).141 Despite induc-
ing a significant decrease in peripheral eosinophil levels, 
mepolizamab was associated with significant improvement 
in symptoms (by physican global assessment) in only 4/18 
patients (22%) compared with 1/22 patients (4.6%) treated 
with placebo. Modest (,50%) improvement was seen in 
significantly more patients treated with mepolizumab (13/18, 
72%) compared to placebo (9/22, 41%).141 Only mild and 
temporary adverse effects were noted. It is possible that a 
longer trial would show increased benefit.
Other agents.  Rituximab is a chimeric monoclonal antibody 
against CD20, a surface antigen on B lymphocytes. Bind-
ing of rituximab to its ligand induces cell lysis. It has been 
proposed that the complex immune dysregulation of AD 
may involve B cells directly or indirectly.113 Six patients with 
severe atopic eczema received rituximab (1 g intravenous, 
two doses separated by two weeks) and all showed clinical 
improvement within 4 to 8 weeks.142
Biologic therapy for AD: summary.  In a 2009-published 
review of the available literature on the safety and efficacy of 
biologic agents for AD, Bremmer et al. identified no reported 
type-I immediate   hypersensitivity   reactions among 261 
patients.113 Regarding efficacy, the authors concluded that 
interferon-γ remains the agent with the best-proven efficacy, 
though its significant drawbacks (low percentage of respond-
ers, daily subcutaneous dosing, and high cost) preclude its 
widespread use.113
Two notable events have occurred since that review. 
First, a biologic agent, efalizumab, which had been stud-
ied for possible efficacy in severe AD, has been removed 
from the market for safety concerns. Second, an additional 
  randomized controlled trial showing efficacy of omalizumab 
in severe asthma-associated AD was published.135 It is thus 
possible that this agent, or perhaps another with a similar 
(or   different) mechanism of action, will find a place in 
the therapeutic armamentarium. Clearly, biologic agents 
are a part of a rapidly changing therapeutic landscape. As 
severe AD remains a disease without ideal management 
options, further trials of these medications are needed and 
warranted.
Ancillary therapies.  Oral antihistamines are commonly 
used to manage the pruritus and sleeplessness associated 
with AD.143,144 Evidence supporting these medications as 
a primary treatment for AD is generally lacking, though 
they are widely used for symptom control and relief of 
underlying allergic conditions and urticaria.144 Random-
ized controlled studies have supported the antipruritic 
effect of cetirizine, levocetirizine, fexofenadine, loratadine, 
and hydroxyzine in helping to control these symptoms in 
patients with AD.145–149 In contrast, chlorpheniramine and 
terfenadine were found to be ineffective at improving noc-
turnal itching and scratching behavior.150,151 In addition to 
antihistamine therapy, the leukeotriene receptor antagonist 
montelukast was found to be effective at relieving symptoms 
of AD in two trials.152,153
Secondary infections (often with Staphylococcus 
aureus) are common in patients with AD and may be 
associated with disease flares.154 Treatment of secondary 
infection with measures including oral antibiotics (eg, 
cephalexin), topical antibiotics (mupirocin) and dilute 
bleach baths have been shown to decrease the clinical 
severity of eczema in patients with signs of secondary 
infection.155
Novel therapies. A pilot study of 12 children with local-
ized chronic atopic eczema demonstrated improvement 
in eczema severity after a single treatment with pulsed 
dye (595 nm) laser. The authors suggest that dermal vas-
culature (targeted by the laser energy at this wavelength) 
interacts with cutaneous immunity to impact eczema 
activity.156Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Conclusion
Chronic AD is a prevalent disease that presents with a wide 
range of severity and a tendency for periodic disease flares. 
As evidenced by this review, a broad number of treatment 
options are available. All cases will benefit from a gentle skin 
care regimen including mild cleansers and emollients. Most 
cases of AD will be adequately managed with topical therapy. 
Topical corticosteroids of the appropriate potency and dura-
tion remain front-line treatment, though many patients will 
benefit from intermittent use of topical calcineurin inhibitors. 
Persistent or severe cases may require periods of systemic 
therapy. It is important to carefully weigh the risks and benefits 
of any therapy. Optimal management will be tailored to the 
individual and will often involve multimodal strategies.
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